RxSight (RXST) Q3 2026 Earnings Call Transcript

RxSight’s Q3 2026 revenue fell 19% year over year to $24.6 million, while LAL procedure volume declined 11% to 23,128 units and gross margin dropped to 73.6% from 79.9%. The company reported a $16.2 million net loss; management cited competition, seasonality and disruption from its commercial reorganization. Management expects Q4 LAL sales to be more in line with Q2, implying mid- to high-single-digit sequential growth, and expects lower operating expenses in 2027; cash and investments were $254.7 million, including Alcon’s $60 million upfront payment.

Analysis

RXST’s key issue is not simply competitive sampling; it is whether utilization can be made durable without permanently higher selling costs. Management’s own evidence points to intensive rep coverage and practice workflow support as drivers at stronger accounts. That makes the near-term sales-force build a test of operating leverage: if added touches lift procedures per installed device, the commercial spend can scale; if not, lower 2027 OpEx may be offset by weaker growth and lost share. The quarter’s restructuring and territory remap also make Q4’s expected sequential rebound a poor standalone proof point.

In the next 1–3 months, watch procedure volume and utilization by existing accounts, not just total revenue: a seasonal rebound could mask continued competitive displacement. The claimed 2027 cost savings are unquantified, so verify actual expense run-rate and cash burn before assigning value to them. The $60 million Alcon payment reduces near-term financing concern, but it is not recurring demand; partnership milestones and commercial conversion remain to be demonstrated. A next-generation product targeted no earlier than 2028 does little to resolve the current execution problem.

Contrarian angle: free trials may temporarily divert cases rather than establish lasting preference, while surgeon workflow and patient outcomes could support RXST’s niche. But management’s confidence in product differentiation is not independent evidence that trialing converts back. JNJ is a plausible competitive exposure given the call’s discussion of new lens trialing, but attribution and share impact are unverified. A sustained recovery in installed-base utilization would falsify the bear case; continued declines despite a trained, fully deployed sales team would validate it.

Key Decisions for Investors

• Keep RXST underweight rather than buy the Q4 rebound narrative. Reassess after the next report, prioritizing procedure volumes and utilization in existing accounts over sequential revenue alone.
• A tactical short RXST is reasonable only if Q4 results fail to approach the indicated Q2-like LAL level, or if subsequent reporting shows continued procedure declines after the sales team is deployed. Size modestly: a seasonal recovery, strong account-level adoption, and the cash position can drive sharp countertrend moves.
• Do not treat the Alcon upfront payment as proof of recurring partnership economics or use it alone to justify a long in ALC. Track disclosed collaboration milestones and evidence of conversion into commercial activity.
• Watch gross margin and inventory-reserve disclosures alongside volume. Stabilizing reserves and improving utilization would weaken the downside thesis; further reserve charges or volume softness would strengthen it.